Propanc Biopharma, Inc. Common Stock Cash Flow-to-Debt Ratio
Propanc Biopharma, Inc. Common Stock cash flow-to-debt ratio. Propanc Biopharma, Inc. Common Stock (PPCB) has a Cash Flow-to-Debt Ratio of -0.50x as of June 2026, meaning its operating cash flow of $-1.70 Million could theoretically repay -1% of its total liabilities ($3.38 Million) in one year. Check Propanc Biopharma, Inc. Common Stock cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Propanc Biopharma, Inc. Common Stock (2010–2026)
Cash flow-to-debt ratio of Propanc Biopharma, Inc. Common Stock from 2010 to 2026. Historical debt coverage capacity for Propanc Biopharma, Inc. Common Stock across 17 annual periods. Check how aggressively does Propanc Biopharma, Inc. Common Stock reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Propanc Biopharma, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2010–2026)
Propanc Biopharma, Inc. Common Stock cash flow-to-debt ratio by year from 2010 to 2026. Year-by-year debt coverage analysis for Propanc Biopharma, Inc. Common Stock. For the full cash flow conversion analysis, see PPCB cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -1.68x | $-5.68 Million | $3.38 Million | ▼ -2277.1% |
| 2025 | -0.07x | $-405.17K | $5.73 Million | ▲ +70.9% |
| 2024 | -0.24x | $-935.12K | $3.85 Million | ▲ +30.2% |
| 2023 | -0.35x | $-1.11 Million | $3.18 Million | ▲ +24.8% |
| 2022 | -0.46x | $-1.44 Million | $3.11 Million | ▼ -24.4% |
| 2021 | -0.37x | $-1.15 Million | $3.08 Million | ▲ +24.8% |
| 2020 | -0.49x | $-1.85 Million | $3.74 Million | ▼ -5.7% |
| 2019 | -0.47x | $-2.06 Million | $4.40 Million | ▼ -46.6% |
| 2018 | -0.32x | $-2.18 Million | $6.82 Million | ▲ +17.9% |
| 2017 | -0.39x | $-2.15 Million | $5.54 Million | ▲ +76.2% |
| 2016 | -1.63x | $-4.80 Million | $2.94 Million | ▼ -320.6% |
| 2015 | -0.39x | $-1.43 Million | $3.68 Million | ▼ -160.5% |
| 2014 | -0.15x | $-226.44K | $1.52 Million | ▲ +8.2% |
| 2013 | -0.16x | $-128.65K | $794.22K | ▲ +44.4% |
| 2012 | -0.29x | $-170.28K | $584.19K | ▲ +93.6% |
| 2011 | -4.55x | $-1.40 Million | $306.85K | ▼ -448.0% |
| 2010 | -0.83x | $-191.51K | $230.76K | — |